Related Experiment Video
Updated: Mar 30, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
96.2K
Peptide modulators of alpha-glucosidase
Irena Roskar1, Peter Molek2, Miha Vodnik2
1Entrapharm d.o.o., University of Ljubljana Ljubljana, Slovenia.
Journal of Diabetes Investigation
|November 7, 2015
Summary
Researchers screened peptide libraries to find new modulators for alpha-glucosidase, an enzyme linked to type 2 diabetes. Two cyclic peptides effectively inhibited the enzyme, showing promise for developing novel antidiabetic drugs.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Postprandial glucose spikes in type 2 diabetes increase cardiovascular risk.
- Targeting alpha-glucosidase is a key therapeutic strategy for diabetes management.
Purpose of the Study:
- To identify novel peptide modulators of mammalian intestinal alpha-glucosidase.
- To explore peptides as potential leads for antidiabetic drug development.
Main Methods:
- Screening of three phage-displayed peptide libraries against mammalian alpha-glucosidase.
- Selection of target-binding peptides using different elution strategies.
- Synthesis and evaluation of four top-performing peptides for enzyme binding and activity modulation.
Main Results:
- Isolation of two linear and two cyclic heptapeptides with high affinity for alpha-glucosidase.
- Demonstration that both cyclic peptides inhibited enzyme activity.
- Observation that linear peptides, conversely, increased enzyme activity.
Conclusions:
- Novel peptide modulators of alpha-glucosidase were successfully identified.
- Selected peptides, particularly cyclic ones, show potential as alpha-glucosidase inhibitors.
- Further optimization via peptidomimetic design could enhance their therapeutic efficacy.
More Related Videos
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
859
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
859
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
01:16Hormones Regulating Blood Glucose
8.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
8.5K
01:06Oral Hypoglycemic Agents: Glinides
938
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
938
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
931
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
931